These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 16952108)
1. Allergic contact dermatitis caused by latanoprost ophthalmic solution. Lai CH; Lai IC; Chi CC Eur J Ophthalmol; 2006; 16(4):627-9. PubMed ID: 16952108 [TBL] [Abstract][Full Text] [Related]
2. Eyelid hypertrichosis associated with latanoprost is reversible. O'Toole L; Cahill M; O'Brien C Eur J Ophthalmol; 2001; 11(4):377-9. PubMed ID: 11820311 [TBL] [Abstract][Full Text] [Related]
3. Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops. Pérez-Rodríguez E; González-Pérez R; Poza P; Feliciano L; López-Correcher B; Matheu V Contact Dermatitis; 2008 Jun; 58(6):370-1. PubMed ID: 18503690 [No Abstract] [Full Text] [Related]
4. Allergic contact dermatitis to latanoprost. Jerstad KM; Warshaw E Am J Contact Dermat; 2002 Mar; 13(1):39-41. PubMed ID: 11887105 [TBL] [Abstract][Full Text] [Related]
5. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Sakata R; Shirato S; Miyata K; Aihara M Eye (Lond); 2014 Dec; 28(12):1446-51. PubMed ID: 25233818 [TBL] [Abstract][Full Text] [Related]
6. Increased eyelid pigmentation associated with use of latanoprost. Kook MS; Lee K Am J Ophthalmol; 2000 Jun; 129(6):804-6. PubMed ID: 10926995 [TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus dermatitis in patients using latanoprost. Morales J; Shihab ZM; Brown SM; Hodges MR Am J Ophthalmol; 2001 Jul; 132(1):114-6. PubMed ID: 11438068 [TBL] [Abstract][Full Text] [Related]
9. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. Inoue K; Shiokawa M; Wakakura M; Tomita G J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280 [TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098 [TBL] [Abstract][Full Text] [Related]
12. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA; Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866 [TBL] [Abstract][Full Text] [Related]
13. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467 [TBL] [Abstract][Full Text] [Related]
14. Latanoprost-induced prostaglandin-associated periorbitopathy. Tan J; Berke S Optom Vis Sci; 2013 Sep; 90(9):e245-7; discussion 1029. PubMed ID: 23912967 [TBL] [Abstract][Full Text] [Related]
15. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690 [TBL] [Abstract][Full Text] [Related]
16. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940 [TBL] [Abstract][Full Text] [Related]
17. Ocular complications of latanoprost in uveitic glaucoma: three case reports. Saccà S; Pascotto A; Siniscalchi C; Rolando M J Ocul Pharmacol Ther; 2001 Apr; 17(2):107-13. PubMed ID: 11324978 [TBL] [Abstract][Full Text] [Related]
18. Latanoprost : an update of its use in glaucoma and ocular hypertension. Perry CM; McGavin JK; Culy CR; Ibbotson T Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627 [TBL] [Abstract][Full Text] [Related]
19. Heart block following topical latanoprost treatment. De Smit E; Theodorou M; Hildebrand GD; Bloom P BMJ Case Rep; 2011 Oct; 2011():. PubMed ID: 22679164 [TBL] [Abstract][Full Text] [Related]
20. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD; Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]